CIM

Itolizumab Phase 3 Clinical Trials to Begin in US, Mexico and Brazil

Itolizumab, a monoclonal antibody developed by the Center of Molecular Immunology (CIM) in collaboration with Biocon, India's largest pharmaceutical company,…

5 years ago

CIM to Launch CIMAvax on the International Market

After 25 long years of studies and innumerable clinical trials which took place in Canada, the United Kingdom, Malaysia, China…

6 years ago

New Anti Cancer Drugs from the Center of Molecular Immunology

Established in 1991, the Center of Molecular Immunology (Centro de Inmunologia Molecular) (CIM) situated in Playa, west of Havana, is…

8 years ago